Publication date: Apr 15, 2019 * Overview of Common Eye & Vision Changes Related to Cancer Treatments * Causes & Risk Factors * Discussion of Common Eye & Vision Changes ... Read more

Publication date: Apr 17, 2019 Flavia Fontana, MSc. Pharm., Drug Research Program, Faculty of Pharmacy, University of Helsinki (FIN) 22. Targeting and Drug Delivery in Nanomedicine and Precision Medicine CLINAM ... Read more

Publication date: Apr 15, 2019 Concepts Keywords Melanoma Health Medicine Neoplasms Cancer RTT Melanoma DecisionDx-UM Semantics Type Source Name pathway BSID Melanoma disease DOID Melanoma disease MESH Melanoma Similar Circulating ... Read more

Publication date: Apr 09, 2019 Concepts Keywords Melanoma Clinical trial RTT Melanoma Cancer Clinical medicine Medicine Health Vemurafenib Semantics Type Source Name pathway BSID Melanoma disease DOID Melanoma disease MESH ... Read more

Publication date: Apr 05, 2019 There’s no questions that sun exposure increases your risk of skin cancer. According to the Centers for Disease Control and Prevention, skin cancer is the ... Read more

Publication date: Apr 05, 2019 Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination ... Read more

Publication date: Apr 03, 2019 City of Hope skin cancer expert Morganna Freeman, D.O., discusses immunotherapy for treating melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2019. ... Read more

Publication date: Apr 03, 2019 City of Hope’s Kim Margolin, M.D., gives insight on how our understanding of checkpoint inhibitors for the treatment of cancers is evolving at the American ... Read more

Publication date: Mar 30, 2019 CRISPR/Cas9 genome-editing technology is a powerful new tool for developing cell-based models with disease-relevant mutations. In this presentation, we describe how this advanced technology was ... Read more

Publication date: Mar 29, 2019 Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in ... Read more